Cutaneous Squamous Cell Carcinoma: Prompt Diagnosis and Expanding Management Options for Metastatic Disease

View Activity

FACULTY

Nikhil I. Khushalani, MD
Vice Chair and Senior Member, Department of Cutaneous Oncology
Chief, Medical Oncology, H. Lee Moffitt Cancer Center
Associate Professor, Department of Oncologic Sciences
USF Morsani College of Medicine
Tampa, FL

PROGRAM OVERVIEW

This case-based activity will cover the treatment and management of patients with cancer who are treated for or are eligible for treatment for advanced or metastatic cutaneous squamous cell carcinoma.

TARGET AUDIENCE

This activity is designed to meet the educational needs of surgical dermatologists, dermatologists, head and neck surgical oncologists, medical oncologists, and other healthcare practitioners who care for patients with advanced or metastatic cutaneous squamous cell carcinoma.

LEARNING OBJECTIVES

Upon completion of the program, attendees should be able to:

  • Describe the emerging immunotherapy clinical trial data in the treatment of advanced or metastatic cutaneous squamous cell carcinoma.

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity is planned and produced in accordance with ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this online activity for a maximum of 0.5 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent for their participation in the online activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the long-term treatment and management of patients with carcinoma. CNE Credits: 0.5 ANCC Contact Hour(s)

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME)
Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturers of any commercial products and/or providers of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Khushalani has disclosed receiving institutional research funding from Bristol-Meyers Squibb, Merck, Amgen, GSK, HUYA, Regeneron, and Novartis; has been on an advisory board for HUYA, Bristol-Meyers Squibb, EMD Serono, Genentech, Regeneron, Merck, and Immunocore; participated on a data safety monitoring board for AstraZeneca; and has stock ownership in TransEnterix, Mazor Robotics, Bellicum, and Amarin.

CME Content Review
The content of this activity was independently peer-reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer-reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Melissa A Johnson, Sr. Program Manager of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Stephanie S. Wenick, MPhil, Scientific and Medical Services of Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures.
2. Participate in the online activity.
3. Submit the evaluation form to Med Learning Group.

You will receive your certificate after completion of the activity.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science-based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement
information at http://medlearninggroup.com/privacy‐policy/

RELEASE DATE: March 1, 2019

EXPIRATION DATE: March 1, 2020

View Activity

Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.